Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
Arcus Biosciences
Short Term - We look to Buy at 27.75 (stop at 25.94)
Daily signals are bullish. A weaker opening is expected to challenge bullish resolve. Prices expected to stall near trend line support. Dip buying offers good risk/reward. Further upside is expected although we prefer to buy into dips close to the 27.00 level.
Our profit targets will be...
This BioScience company has many products in the testing phases through to the FDA approvals. The stock has also missed earnings multiple times in the past and that is the majority reason why it is currently failing. keep a watch on this to see if it hits new lows and can be a great buy if one of the FDA approvals approaches and the company could see significant...
Phase 2 data expected 2Q 2021 based on BioPharm catalyst website. Gilead have been buying as well as another insider. Watch for a break of 36.13. Stop signal 26.44. Momentum target.
RCUS releases phase one clinical trial data for a drug they are developing to treat pancreatic cancer on Friday, January 15-17. Look to buy about a week in advance.
RCUS has reacted higher after bouncing from a confluence of support:
1) 200 EMA
2) 50% retracement
3) VWAP from all time low
*You can see how the 200 EMA and VWAP from all time low previously acted as the floor back in March
-Now supported strongly by 50 EMA, RCUS closed above the 50 EMA every day this week, and 7 of the last 8 days, with the exception appearing...
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The firm compete in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
1. tremendous drop in the first hour on Friday with a modest rebound, showing the initial overreaction had passed.
2. close above the Strong bottom support line
3. Friday's slump left a big Gap above!
3. there are 2 resistance line near above. Once opening above the first resistance line which is 9.06, the space going up is huge!
Stop loss price can be set at...
